aTyr Pharma, Inc. (ATYR NASDAQ) stock market data APIs
$0.6988
-0.01(-1.4%)
as of November 18, 2025
Try our APIs with
free plan!
aTyr Pharma, Inc. Financial Data Overview
Price chart is built with
Anychart
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Prev. Close
0.6988
Open
0.6876
High
0.7231
Low
0.6858
52 wk Range
0.676-7.29
Market Cap
68 689 K
Shares Outstanding
97 987 K
Revenue
190 K
EPS
-0.26
Beta
0.566
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with aTyr Pharma, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get aTyr Pharma, Inc. data using free add-ons & libraries
Get aTyr Pharma, Inc. Fundamental Data
aTyr Pharma, Inc. Fundamental data includes:
- Net Revenue: 190 K
- EBITDA: -77 978 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
aTyr Pharma, Inc. News
New
DEADLINE ALERT for MRX, ATYR, and WPP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-trade...
aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations...
ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 a...
Bragar Eagel & Squire, P.C. Reminds Stockholders of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights Before Upcoming Deadlines
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of st...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
